Lung · 20 Nov 2026
Effect of Nerandomilast in US Patients with Idiopathic Pulmonary Fibrosis: a Subgroup Analysis of the FIBRONEER-IPF Trial
Justin M. Oldhamh-index 22, Toby M. Maher, Amy L. Olson, Hui Gu, Donald F. Zoz, Ganesh Raghu, Fernando J. Martinezh-index 27
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Purpose In the placebo-controlled FIBRONEER-IPF trial in patients with IPF, nerandomilast reduced decline in forced vital capacity (FVC), with benefits on clinical outcomes and favorable safety and tolerability. We evaluated the effects of nerandomilast in the US patients. Methods Patients were randomized to receive nerandomilast 9 mg bid, nerandomilast 18 mg bid, or placebo, stratified by antifibrotic therapy (nintedanib/pirfenidone versus neither). In the US subgroup, we assessed change in FVC at week 52; time-to-event endpoints over the whole trial; adverse events over the whole trial. Results Of 1177 patients, 196 (16.7%) were from the US. In US patients, adjusted mean (SE) changes in FVC (mL) were − 257.9 (33.6) with placebo, − 152.7 (32.9) with nerandomilast 9 mg bid (difference vs. placebo 105.2 [95% CI 13.0, 197.4]), and − 126.2 (36.9) with nerandomilast 18 mg bid (difference vs. placebo 131.7 [95% CI 33.8, 229.6]. Compared with placebo, the hazard ratios for time to first acute exacerbation of IPF, hospitalization for respiratory cause, or death were 0.91 (95% CI 0.49, 1.67) for nerandomilast 9 mg bid and 0.60 (95% CI 0.30, 1.22) for nerandomilast 18 mg bid. Adverse events led to treatment discontinuation in 17.1%, 12.9% and 10.7% of the placebo, nerandomilast 9 mg bid and nerandomilast 18 mg bid groups, respectively. Conclusion The effects of nerandomilast 18 mg bid in US patients in the FIBRONEER-IPF trial were consistent with the overall population. Nerandomilast 18 mg bid slowed FVC decline, with numerical reductions in the risk of clinical outcomes, and favorable safety and tolerability.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Fernando J. Martinez has the highest h-index among the authors (27).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (20)
What it cites, from open citation data, with Crossref's record of each.